Exelixis
EXEL
#1696
Rank
ยฃ7.79 B
Marketcap
ยฃ27.31
Share price
-3.83%
Change (1 day)
48.27%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): ยฃ1.62 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is ยฃ1.63 Billion. In 2023 the company made a revenue of ยฃ1.43 Billion an increase over the revenue in the year 2022 that were of ยฃ1.33 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) ยฃ1.62 B12.77%
2023 ยฃ1.43 B7.88%
2022 ยฃ1.33 B25.27%
2021 ยฃ1.06 B46.73%
2020 ยฃ0.72 B-1.83%
2019 ยฃ0.73 B9.72%
2018 ยฃ0.67 B100.91%
2017 ยฃ0.33 B115.77%
2016 ยฃ0.15 B518.57%
2015 ยฃ25.08 M55.52%
2014 ยฃ16.12 M-15.1%
2013 ยฃ18.99 M-35.29%
2012 ยฃ29.35 M-84.25%
2011 ยฃ0.18 B55.46%
2010 ยฃ0.11 B27.82%
2009 ยฃ93.78 M16.62%
2008 ยฃ80.41 M40.79%
2007 ยฃ57.11 M13.39%
2006 ยฃ50.37 M14.36%
2005 ยฃ44.04 M59.99%
2004 ยฃ27.53 M-4.44%
2003 ยฃ28.81 M4.23%
2002 ยฃ27.64 M-2.26%
2001 ยฃ28.28 M70.49%
2000 ยฃ16.58 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
ยฃ31.68 B 1,833.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ42.12 B 2,470.48%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ49.73 B 2,934.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ37.34 B 2,178.78%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ25.61 B 1,462.93%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ69.03 B 4,112.92%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ47.31 B 2,787.73%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ8.07 M-99.51%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ74.24 M-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA